Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
Author(s): Jose L Batista , Tracy Makuvire , Jonathan D Davis , et al Added: 1 month ago

Cardiovascular Kidney Metabolic

Heart Failure
Enlicitide: Oral PCSK9 Inhibitor Lowers LDL-C by 56%
Added: 1 month ago Source:  Radcliffe Cardiology
Written by Mirjam Boros, Radcliffe CardiologyA new oral proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitor, enlicitide, has demonstrated a significant reduction in low-density lipoprotein cholesterol (LDL-C) levels in patients with or at risk of atherosclerotic cardiovascular disease (ASCVD), according to results from the CORALreef Lipids trial.¹Mechanism of ActionEnlicitide is an… View more

Cardiovascular Kidney Metabolic

Prevention & Chronic Conditions
AHA 25: The CORALreef HeFH Trial
Author(s): Christie Ballantyne Added: 5 months ago
AHA Scientific Sessions 2025 - Dr Christie Ballantyne (Baylor College of Medicine, Houston, TX, US) discusses findings from the CORALreef HeFH trial, examining the efficacy and safety of enlicitide decanoate, an oral PCSK9 inhibitor, in adults with heterozygous familial hypercholesterolemia.This Phase 3, randomized, double-blind, placebo-controlled study evaluated 303 participants with… View more

Cardiovascular Kidney Metabolic
SGLTi and GLP-1 in HF
Author(s): Jose L Batista , Tracy Makuvire , Jonathan D Davis , et al Added: 11 months ago

Cardiovascular Kidney Metabolic

Heart Failure
A Michael Lincoff
Research Area(s) / Expertise:
Dr A. Michael Lincoff, MD, assumes the role of Vice Chairman within the Robert and Suzanne Tomsich Department of Cardiovascular Medicine, acting as an interventional cardiologist at the Sydell and Arnold Miller Family Heart, Vascular & Thoracic Institute at Cleveland Clinic.With a purview extending beyond clinical practice, Dr Lincoff spearheads clinical research endeavours throughout the… View more
Research Area(s) / Expertise: Job title: Professor
Marco Metra is Full Professor of Cardiology and Director of the Institute of Cardiology of the Civil Hospital and University of Brescia, Italy, and Editor-in-Chief of theEuropean Journal of Heart Failureand Senior Consulting Editor of theEuropean Heart Journal. Prof Metra has been principal investigator and member of the Executive or Steering Committees of many trials in patients with heart… View more
The Evolving Treatment Landscape for HFpEF in Cardiac Amyloidosis
Author(s): Added: 5 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview… View more

Heart Failure
Bridging the Gap in Cardio-Renal Care
Author(s): Paola Fioretto , Rajiv Agarwal Added: 10 months ago
Filmed on location at ERA 2025 in Vienna, Austria, this three-part video series brings together internationally recognised experts Prof Rajiv Agarwal (Indiana University School of Medicine, Indianapolis, US) and Prof Paola Fioretto (University of Padova, Padova, IT) for an insightful peer-to-peer discussion on the latest advances in chronic kidney disease (CKD) and cardio-renal management… View more

Cardiovascular Kidney Metabolic

Guidelines & Statements
Your Questions Answered: Revolutionising Thrombosis Treatment in ACS, SSP and AF
Author(s): Carolyn Lam, Jeffrey Weitz, Sneha Shah Jain Start date: Oct 06, 2025
Following the ESC 2025 symposium 'Revolutionising Thrombosis Treatment in ACS, SSP and AF – Bridging the Gaps With Next Generation Anticoagulation Strategies', this live Q&A webinar offers an exclusive chance to continue the conversation.Join Prof Carolyn Lam (Singapore, UK), Prof Jeffrey Weitz (Hamilton, CA) and Dr Sneha Shah Jain (Stanford, US) as they address your questions on stroke… View more

Anticoagulation

Electrophysiology & Arrhythmia
ACC 25 Late-Breaking Discussion: The ADVANCE-HTN Trial
Author(s): Harriette Van Spall , Luke Laffin Added: 1 year ago
ACC 25 - ADVANCE-HTN shows lorundrostat, an aldosterone synthase inhibitor, effectively lowered 24-hour blood pressure in patients with uncontrolled and true resistant hypertension.Late-breaker discussion host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Dr Luke Laffin (Cleveland Clinic, Cleveland, OH, US) to discuss the key findings from the ADVANCE-HTN trial… View more

Prevention & Chronic Conditions